JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bramson, H. N.
Right arrow Articles by Frye, S. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bramson, H. N.
Right arrow Articles by Frye, S. V.

Vol. 282, Issue 3, 1496-1502, 1997

Unique Preclinical Characteristics of GG745, A Potent Dual Inhibitor of 5AR

H. Neal Bramson, David Hermann, Kenneth W. Batchelor, Frank W. Lee, Michael K. James and Stephen V. Frye

Department of Clinical Pharmacology (D.H.), Divisions of Biochemistry (H.N.B.) and Metabolic Diseases Research (K.W.B.), Bioanalysis and Drug Metabolism (F.W.L.), and Chemistry (S.V.F.), Glaxo Wellcome Research Institute, Research Triangle Park, North Carolina, and Inspire Pharmaceuticals Inc., Durham, North Carolina (M.K.J.)

Selective inhibition of type 2 5alpha -reductase has been shown to be efficacious in the treatment of benign prostatic hyperplasia. Pharmacokinetic and pharmacodynamic results are reported of treatment with a potent inhibitor of both 5alpha -reductase isozymes, GG745, in rats, dogs and men. In the rat, GG745 has a similar effect on DHT-driven prostatic growth as finasteride, another dual 5alpha -reductase inhibitor in this species. However, GG745 appears to be more potent in the rat, a result that likely reflects the greater inherent potency and terminal half-life of GG745 (14 hr) compared with that of finasteride (1 hr). These pharmacokinetic differences are also maintained in the dog (65 and 4 hr for GG745 and finasteride, respectively). From these results, the literature, and in vitro studies, we estimated doses of GG745 likely to prove efficacious in reducing DHT levels in man. These estimated values were predictive of single-dose effects of GG745 in man. Results from single-dose evaluations in man indicate that GG745 has a terminal half-life of ~240 hr, and single doses of >10 mg decreased DHT levels significantly more than did single 5-mg doses of finasteride. These data support the hypothesis that a molecule (GG745) that effectively inhibits both 5alpha -reductases will lower serum DHT levels significantly more than a molecule that inhibits only a single 5alpha -reductase isozyme (e.g., finasteride, a selective inhibitor of the type 2 enzyme in man).

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
J. K. Amory, C. Wang, R. S. Swerdloff, B. D. Anawalt, A. M. Matsumoto, W. J. Bremner, S. E. Walker, L. J. Haberer, and R. V. Clark
The Effect of 5{alpha}-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1659 - 1665.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
S. S Connolly and J. M Fitzpatrick
Medical treatment of benign prostatic hyperplasia
Postgrad. Med. J., February 1, 2007; 83(976): 73 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J. P Wiebe
Progesterone metabolites in breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 717 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Xu, S. L. Dalrymple, R. E. Becker, S. R. Denmeade, and J. T. Isaacs
Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers.
Clin. Cancer Res., July 1, 2006; 12(13): 4072 - 4079.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Iranmanesh and J. D. Veldhuis
Combined Inhibition of Types I and II 5 {alpha}-Reductase Selectively Augments the Basal (Nonpulsatile) Mode of Testosterone Secretion in Young Men
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4232 - 4237.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
N. Makridakis and J. K V Reichardt
Pharmacogenetic analysis of human steroid 5{alpha} reductase type II: comparison of finasteride and dutasteride
J. Mol. Endocrinol., June 1, 2005; 34(3): 617 - 623.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. V. Clark, D. J. Hermann, G. R. Cunningham, T. H. Wilson, B. B. Morrill, and S. Hobbs
Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5{alpha}-Reductase Inhibitor
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2179 - 2184.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. J. VanDoren, D. B. Matthews, G. C. Janis, A. C. Grobin, L. L. Devaud, and A. L. Morrow
Neuroactive Steroid 3alpha -Hydroxy-5alpha -Pregnan-20-One Modulates Electrophysiological and Behavioral Actions of Ethanol
J. Neurosci., March 1, 2000; 20(5): 1982 - 1989.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.